CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients

Sara Pelucchi1, Raffaella Mariani, Stefano Calza

  • 1Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy.

Haematologica
|July 10, 2012
PubMed

Insights

Genetic factors influence hereditary hemochromatosis (HH) expression in HFE p.C282Y homozygotes. While CYBRD1 variants show associations, no single polymorphism significantly modifies HH phenotype, suggesting complex genetic interactions.

Area of Science:

  • Genetics
  • Iron Metabolism
  • Human Physiology

Background:

  • Hereditary hemochromatosis (HH) is often associated with the HFE p.C282Y mutation in Caucasians.
  • Significant variability exists in HH penetrance and expression among individuals with the same HFE genotype.
  • Environmental and additional genetic factors likely contribute to HH phenotype variability.

Purpose of the Study:

  • To investigate the role of genetic variations in iron metabolism genes on HH phenotype.
  • To identify single nucleotide polymorphisms (SNPs) associated with iron overload markers in p.C282Y homozygous Italians.
  • To assess the predictive value of these genetic variants for adverse HH phenotypes.

Main Methods:

  • Analysis of 214 SNPs in 50 iron metabolism genes.
  • Association testing with serum ferritin, iron removed, and transferrin saturation in 296 p.C282Y homozygous Italians.
  • Linear regression models adjusted for age, sex, and alcohol consumption.

Main Results:

  • Seventeen genetic variants showed potential additive effects on iron overload markers.
  • A significant association was found between CYBRD1 SNP rs3806562 and transferrin saturation.
  • This SNP (rs3806562) appears to be a marker for a functional variant (rs884409) influencing serum ferritin, but rs3806562 itself lacks direct functional impact.

Conclusions:

  • Polymorphisms in iron metabolism genes, particularly CYBRD1, may modulate HH penetrance.
  • No single identified polymorphism acts as a major modifier of the HH phenotype.
  • The findings support a complex genetic architecture underlying HH phenotype variability.
Abstract

Related Concept Videos

Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genetic Lingo01:11

Genetic Lingo

Overview